Legal proceedings between Pfizer and Poland over unfulfilled COVID-19 vaccine orders are drawing renewed attention to the contractual structure underpinning the European Union’s joint procurement strategy during the pandemic.
The case, being handled in Belgian courts where the relevant contracts are governed, relates to Poland’s 2022 decision to suspend acceptance of further vaccine deliveries agreed under a 2021 framework negotiated by the European Commission. While figures circulating in the market suggest Poland’s potential financial exposure could reach into the range of €1 billion, no final court ruling has been publicly confirmed to date.
At the core of the dispute are Advance Purchase Agreements concluded at EU level with vaccine manufacturers, most notably a May 2021 deal with BioNTech/Pfizer for up to 1.8 billion doses. The Commission negotiated these agreements on behalf of Member States under a joint procurement mechanism established during the health crisis. Participation in the scheme was voluntary, but once individual countries opted in and confirmed volumes, they became contractually bound by the agreed terms.
Poland later argued that the underlying conditions of the agreement had materially changed. Government representatives cited reduced demand as the pandemic evolved, alongside the financial and logistical impact of the war in Ukraine, as justification for halting further deliveries. The country also raised concerns about the proportionality of its contracted volumes relative to actual needs.
Pfizer has maintained that the contracts remain legally binding, and that Member States are required to honour their purchase commitments regardless of subsequent changes in market conditions. The outcome of the case is expected to hinge on the interpretation of these contractual obligations and whether extraordinary circumstances could justify a deviation from agreed terms.
The dispute is being closely watched across the region, as other Member States, including Romania, also adjusted or reduced vaccine orders amid declining demand. While no identical legal proceedings have been confirmed, the Polish case may set an important reference point for how such contracts are enforced.
Beyond the legal dimension, the situation has revived scrutiny of the European Commission’s role in negotiating vaccine supply agreements at the height of the pandemic. Acting under a mandate from Member States, the Commission centralised procurement in an effort to secure supply and strengthen the EU’s collective bargaining position. However, the structure of the agreements left financial responsibility with individual countries.
Questions around transparency have also persisted, particularly regarding the involvement of Commission President Ursula von der Leyen in direct exchanges with Pfizer CEO Albert Bourla during negotiations. While no wrongdoing has been established, the European Ombudsman and other institutions have raised concerns over access to documentation related to these communications.
As the legal process continues, the case underscores the long-term implications of crisis-era procurement decisions. While the EU’s joint approach enabled rapid access to vaccines during the pandemic, it also created binding commitments that are now being tested in a markedly different public health and economic environment.
Source: WEI
